Retatrutide vs Semaglutide

Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction

Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that simultaneously activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, combining the complementary metabolic actions of all three incretin and counterregulatory hormone pathways in a single weekly injection. The GLP-1 component drives satiety and insulin secretion, GIP enhances adipose lipid metabolism and further modulates appetite, and glucagon receptor activation increases energy expenditure — together producing greater weight loss than single or dual agonists in the same receptor class. A Phase 2 randomized controlled trial published in the New England Journal of Medicine demonstrated dose-dependent weight reductions of up to 24% of body weight at 48 weeks, among the largest reported for any pharmacological obesity treatment. Retatrutide has not received FDA approval; it is under Phase 3 registrational evaluation (TRIUMPH trials) as of 2025 for obesity, obstructive sleep apnea, and knee osteoarthritis. Retatrutide cost and access As of mid-2026, retatrutide has not received FDA approval and is not commercially available as a branded pharmaceutical. It is in late-stage (Phase 3) clinical development through Eli Lilly. Access pathways include: enrollment in active clinical trials (listed on ClinicalTrials.gov), research-use peptide vendors who supply retatrutide for laboratory/research contexts (not for human use), and a limited number of compounding pharmacies that compound investigational or pre-approval compounds under provider-supervised protocols. Cost per month of research-grade retatrutide from vendors varies considerably by quantity and formulation. Branded pharmaceutical pricing will be established at approval; given tirzepatide's pricing trajectory and the triple-agonist mechanism, analyst forecasts suggest a premium pricing position relative to existing GLP-1 agonists. Retatrutide vs survodutide: Survodutide (BI 456906, Boehringer Ingelheim + Zealand Pharma) is a dual GLP-1 and glucagon receptor agonist in Phase 3 development for MASH (metabolic dysfunction-associated steatohepatitis) and obesity. Compared to retatrutide, survodutide lacks the GIP receptor component; retatrutide's triple agonism adds GIP-mediated adipose lipid oxidation to the GLP-1 + glucagon combination. In trial comparisons, both compounds show substantial weight reductions (retatrutide 24.2% at 12mg/week in Phase 2; survodutide 18.7% at highest dose in Phase 2). Neither compound has a direct head-to-head trial yet. Both represent the next tier beyond tirzepatide in the GLP-1 + additional agonism category. Retatrutide's MASH indication (liver fat reduction) also overlaps with survodutide's primary development focus. The competitive landscape in this category is evolving rapidly as multiple Phase 3 readouts are expected through 2026–2027.

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is among the most prescribed and searched compounds in the weight loss space. Compounding pharmacies have produced semaglutide formulations under 503A and 503B frameworks, with significant provider interest across the telehealth and functional medicine space. Mechanism of action: Semaglutide activates glucagon-like peptide-1 (GLP-1) receptors in the hypothalamus, brainstem, and pancreas. This triggers a coordinated metabolic response: appetite signals are reduced, gastric emptying is slowed (increasing satiety duration), insulin secretion is potentiated in a glucose-dependent manner, and glucagon secretion is suppressed. The result is reduced caloric intake and improved postprandial glucose regulation. Semaglutide's extended half-life (~7 days) enables once-weekly subcutaneous injection, distinguishing it from earlier GLP-1 agonists that required daily dosing. Clinical evidence: The STEP trial program established semaglutide's weight reduction profile. STEP 1 (2021) found a mean weight reduction of 14.9% over 68 weeks with 2.4mg/week semaglutide (Wegovy dose) vs 2.4% with placebo. STEP 4 demonstrated that discontinuation led to weight regain, indicating ongoing use is required to maintain outcomes. The SUSTAIN trial series confirmed cardiovascular risk reduction in T2D patients. Semaglutide is one of the most extensively studied GLP-1 agonists in large-scale randomised controlled trials. Semaglutide with B12: Some compounding formulations combine semaglutide with vitamin B12 (methylcobalamin) in the same injectable preparation. The rationale is two-fold: nausea and gastrointestinal discomfort are the most commonly reported side effects of GLP-1 agonists (occurring in 15–40% of users in trials), and injectable methylcobalamin bypasses the reduced gastric absorption that can accompany slowed gastric motility. B12 also supports energy metabolism during periods of caloric restriction. Clinical evidence that B12 addition changes weight loss outcomes is limited; the combination is primarily a compounding convention rather than a protocol validated in independent clinical trials. Providers offering compounded semaglutide with B12 formulations are indexed in the PeptideBase directory. Semaglutide vs tirzepatide: Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors. The SURMOUNT-5 head-to-head trial found tirzepatide produced greater weight reductions than semaglutide at comparable doses. Both are FDA-approved and available through licensed prescribers; protocol selection depends on clinical context and provider judgment.